Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity
暂无分享,去创建一个
D. Evans | D. Halliday | James Nicholson | A. Parry | P. Pretorius | G. Anand | K. Lascelles | G. Vassallo | S. Chandratre | M. Wasik | Beatrice Emmanouil | D. Evans | D. Evans
[1] D. Halliday,et al. Neurofibromatosis Type 2–Related Eye Disease Correlated With Genetic Severity Type , 2019, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.
[2] D. Halliday,et al. Progression of hearing loss in neurofibromatosis type 2 according to genetic severity , 2018, The Laryngoscope.
[3] M. Kellett,et al. High‐Grade Glioma is not a Feature of Neurofibromatosis Type 2 in the Unirradiated Patient , 2018, Neurosurgery.
[4] D. Evans,et al. Schwannomatosis: a genetic and epidemiological study , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[5] A. Siddiqui,et al. Cerebral vasculopathy in childhood neurofibromatosis type 2: cause for concern? , 2018, Developmental medicine and child neurology.
[6] D. Halliday,et al. Diagnosis of sporadic neurofibromatosis type 2 in the paediatric population , 2018, Archives of Disease in Childhood.
[7] D. Evans,et al. Hearing optimisation in neurofibromatosis type 2: A systematic review , 2017, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.
[8] D. Evans,et al. Genetic Severity Score predicts clinical phenotype in NF2 , 2017, Journal of Medical Genetics.
[9] M. Giovannini,et al. A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas , 2017, Journal of Neuro-Oncology.
[10] C. Chung,et al. Genetic differences on intracranial versus spinal cord ependymal tumors: a meta-analysis of genetic researches , 2016, European Spine Journal.
[11] E. Harkness,et al. The Contribution of Whole Gene Deletions and Large Rearrangements to the Mutation Spectrum in Inherited Tumor Predisposing Syndromes , 2016, Human mutation.
[12] D. Evans,et al. Neurofibromatosis type 2 service delivery in England. , 2016, Neuro-Chirurgie.
[13] D. G. Evans,et al. Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms. , 2015, Seminars in pediatric neurology.
[14] David Evans,et al. Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients , 2015, Journal of Medical Genetics.
[15] D. Evans,et al. Bilateral vestibular schwannomas in older patients: NF2 or chance? , 2015, Journal of Medical Genetics.
[16] N. Bonne,et al. Causes of mortality in neurofibromatosis type 2 , 2015, British journal of neurosurgery.
[17] A. Muzikansky,et al. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients , 2014, Cancer Chemotherapy and Pharmacology.
[18] D. Evans,et al. Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2 , 2014, Journal of Neurology.
[19] K. Ohno,et al. Characterization of early onset neurofibromatosis type 2 , 2014, Brain and Development.
[20] A. Wallace,et al. Mutation type and position varies between mosaic and inherited NF2 and correlates with disease severity , 2013, Clinical genetics.
[21] A. Quattrone,et al. Natural history of neurofibromatosis type 2 with onset before the age of 1 year , 2013, neurogenetics.
[22] D. Evans,et al. Genetic testing and screening of individuals at risk of NF2 , 2012, Clinical genetics.
[23] A. B. Grayeli,et al. Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. , 2012, Neuro-oncology.
[24] W. Curry,et al. Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients. , 2011, Journal of neurosurgery. Spine.
[25] D. Evans,et al. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset , 2011, Journal of Medical Genetics.
[26] R. Ferner,et al. A qualitative study of the impact of living with neurofibromatosis type 2 , 2011, Psychology, health & medicine.
[27] A. Shenton,et al. Further genotype – phenotype correlations in neurofibromatosis 2 , 2009, Clinical genetics.
[28] M. Lev,et al. Concordance of Bilateral Vestibular Schwannoma Growth and Hearing Changes in Neurofibromatosis 2: Neurofibromatosis 2 Natural History Consortium , 2009, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.
[29] D. Evans,et al. Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification , 2007, Journal of Medical Genetics.
[30] E. Boltshauser,et al. Ophthalmologic findings and long-term course in patients with neurofibromatosis type 2. , 2006, American journal of ophthalmology.
[31] D. Stephens,et al. Psychosocial effects of neurofibromatosis type 2 (Part 1): General effects , 2006 .
[32] D. Evans,et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement , 2005, British journal of neurosurgery.
[33] A. Polizzi,et al. Earliest Clinical Manifestations and Natural History of Neurofibromatosis Type 2 (NF2) in Childhood: A Study of 24 Patients* , 2005, Neuropediatrics.
[34] D. Evans,et al. Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. , 2004, American journal of human genetics.
[35] M. Maccollin,et al. Neurofibromatosis 2 in the Pediatric Population , 2003, Journal of child neurology.
[36] D. Evans,et al. Predictors of the risk of mortality in neurofibromatosis 2. , 2002, American journal of human genetics.
[37] L. Kluwe,et al. Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study. , 2002, Journal of neurosurgery.
[38] J. Jääskeläinen,et al. Mild familial neurofibromatosis 2 associates with expression of merlin with altered COOH-terminus , 2000, Neurology.
[39] D. Evans,et al. Paediatric presentation of type 2 neurofibromatosis , 1999, Archives of disease in childhood.
[40] V. Mautner,et al. The diagnosis and management of neurofibromatosis 2 in childhood. , 1998, Seminars in pediatric neurology.
[41] L. Kluwe,et al. Mosaicism in sporadic neurofibromatosis 2 patients. , 1998, Human molecular genetics.
[42] D. Evans,et al. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. , 1998, Journal of medical genetics.
[43] M. Tatagiba,et al. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. , 1998, American journal of medical genetics.
[44] L. Kluwe,et al. Skin abnormalities in neurofibromatosis 2. , 1997, Archives of dermatology.
[45] L. Kluwe,et al. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes , 1996, Human Genetics.
[46] R. Weksberg,et al. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. , 1996, American journal of human genetics.
[47] S. Pulst,et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2 , 1993, Nature.
[48] D. Evans,et al. A clinical study of type 2 neurofibromatosis. , 1992, The Quarterly journal of medicine.
[49] D. Evans,et al. Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort , 2016, Journal of Neuro-Oncology.
[50] S. Pulst,et al. Neurofibromatosis 2 in the pediatric age group. , 1993, Neurosurgery.